Corvus Pharmaceuticals, Inc.
CRVSNasdaq
$14.90
↑ +4.4%Jul 17 close · end-of-day
Price
1Y↑ +250.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$1.1B
P/E
—
P/S
—
P/B
5.6
EV/EBITDA
—
PEG
—
FCF Yield
-2.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$44.2M
Free Cash Flow (TTM)
-$35.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-18.4%
ROIC
-954.9%
Debt / Equity
—
Net Cash
$236.7M
Return 1Y
+250.6%
Company profile
Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.
- CEO
- Richard A. Miller
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- California
- Website
- corvuspharma.com
Earnings
CRVS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.15↑ +15.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.8M | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M |
| Net income | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
| Diluted EPS | -$0.20 | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 |
| Operating cash flow | -$34.8M | -$36.7M | -$27.0M | -$23.9M | -$25.4M | -$32.8M |
| Free cash flow | -$34.9M | -$36.7M | -$27.3M | -$24.0M | — | -$33.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.9M | -$7.3M | -$8.1M | -$9.9M | -$10.3M | -$10.6M | -$12.2M | -$14.9M |
| Net income | -$4.3M | -$40.2M | -$12.1M | $15.2M | -$8.0M | -$10.2M | -$12.3M | -$13.7M |
| Diluted EPS | -$0.07 | -$0.60 | -$0.23 | -$0.13 | -$0.10 | -$0.12 | -$0.18 | -$0.15 |
| Operating cash flow | -$5.5M | -$6.3M | -$8.5M | -$8.3M | -$5.8M | -$9.6M | -$9.2M | -$10.4M |
| Free cash flow | — | — | — | -$8.3M | -$5.9M | -$9.6M | -$9.2M | -$10.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 23, 2026
Jun 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Moore David Scott | Buy | 21,700 | $11.53 | $250,235.72 | filing |
| 2026-05-18 | MILLER RICHARD A MD· President and CEO | Buy | 5,000 | $12.05 | $60,250.00 | filing |
| 2026-05-18 | MILLER RICHARD A MD· President and CEO | Buy | 1,932 | $12.01 | $23,203.32 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 30,000 | $15.00 | $450,000.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $12.50 | $187,500.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $9.70 | $145,500.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $3.61 | $54,150.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $3.27 | $49,050.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $2.74 | $41,100.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $2.60 | $39,000.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $2.49 | $37,350.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $2.12 | $31,800.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $2.00 | $30,000.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $1.64 | $24,600.00 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $0.99 | $14,848.50 | filing |
| 2026-01-28 | Thompson Peter A. | Option exercise | 15,000 | $0.97 | $14,475.00 | filing |
| 2025-06-27 | Thompson Peter A. | Sale | 1,176,332 | $4.16 | $4.9M | filing |
| 2025-06-27 | ORBIMED ADVISORS LLC | Sale | 1,176,332 | $4.16 | $4.9M | filing |
| 2025-06-27 | ORBIMED ADVISORS LLC | X | 1,397,684 | $3.50 | $4.9M | filing |
| 2025-06-27 | Thompson Peter A. | X | 1,397,684 | $3.50 | $4.9M | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.